ischaemic stroke
Conditions
Interventions
Hyperbaric Oxygen Therapy + Endovascular Treatment:Participants will enter the medical hyperbaric oxygen chamber on the 3rd to 5th day after revascularization treatment. Under the pressure of 2.0 ATA,
Sham Control:Participants will enter the medical hyperbaric chamber for oxygen therapy 3 to 5 days after revascularization. Under a pressure of 1.2 ATA, 21% oxygen will be inhaled through a mask for 6
Sponsors
Ya'an People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: (1) Age = 18 years old; (2) Time from onset to randomization within 24 hours; (3) First acute ischemic stroke confirmed by CT or MRI; (4) NIHSS score ranging from 5 to 25 at onset; (5) ASPECTS score = 5; (6) Large artery occlusion confirmed by cerebral angiography, including internal carotid artery, M1/M2 segment of middle cerebral artery, A1 segment of anterior cerebral artery, P1 segment of posterior cerebral artery, vertebral artery, or basilar artery; (7) Endovascular treatment within 24 hours of onset, including retrievable stent thrombectomy, intra-arterial thrombolysis, catheter aspiration, balloon dilation, stent placement, or combined use of the above methods as recommended by current guidelines; (8) Post-operative mTICI grade reaching 2b or 3; (9) The patient or their family member has signed a written informed consent form.
Exclusion criteria
Exclusion criteria: (1) History of previous stroke; (2) Pre-onset mRS score = 2; (3) Intracranial hemorrhage or subarachnoid hemorrhage confirmed by CT or MRI; (4) Pregnant or lactating women; (5) History of previous oxygen poisoning; (6) Patients with severe dysfunction of vital organs such as heart, lung, liver, and kidney; (7) Inability to withdraw intravenous pumping drugs after 5 days of expected endovascular treatment, or unstable vital signs after withdrawal; (8) Currently participating in other clinical trials; (9) Expected lifespan < 6 months; (10) Contraindications for hyperbaric oxygen therapy, mainly including: 1) Untreated pneumothorax or mediastinal emphysema; 2) Severe emphysema, pulmonary bulla, or bronchiectasis; 3) Second-degree or higher atrioventricular block; 4) Diabetic patients with unstable blood sugar control; 5) Angle-closure glaucoma; 6) Concurrent use of disulfiram (excluding disulfiram-like reactions caused by cephalosporins and other drugs); 7) Concurrent use of antineoplastic drugs such as bleomycin, cisplatin, or doxorubicin; 8) Active internal bleeding and hemorrhagic diseases; 9) History of oxygen poisoning; 10) Tubercular cavities; 11) Unstable vital signs such as temperature, pulse, respiration, or blood pressure; 12) Severe sinusitis; 13) Hypercapnia; 14) Retinal detachment; 15) Claustrophobia; 16) Uncontrolled epilepsy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Functional Independence;Intracranial Hemorrhage; | — |
Secondary
| Measure | Time frame |
|---|---|
| All-cause Mortality;NIHSS;Symptomatic intracranial hemorrhage;Any adverse reactions related to pressurized air therapy; | — |
Countries
China
Contacts
Public ContactJian Wang
Ya'an People's Hospital
Outcome results
None listed